Skip to main content
    M

    Merck & Company Inc (MRK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $144.52
    -3.24 (-2.19%)

    Market Cap: $364.26B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Merck & Company Inc (MRK) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Merck & Company (MRK) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, Merck & Company reported EPS of $2.49, above the $2.12 estimate. It beat the EPS estimate in each of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +11.79%
    Streak
    8 Q

    Upcoming Estimates

    Reports Feb 2, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.76
    Range$1.67 - $2.01
    19 analysts
    Revenue Consensus
    $16.45B
    Range$15.60B - $17.60B
    18 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.13
    Range$1.97 - $2.27
    9 analysts
    EPS Revisions
    2
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$2.21-3.5%
    60d ago$2.21-3.6%
    30d ago$2.16-1.4%
    7d ago$2.130.0%
    Current$2.13
    Revenue Consensus
    $16.45B
    Range$16.14B - $16.82B
    7 analysts

    Next Report

    MRK has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 13.7% below the $2.04 reported for the quarter ended Dec 31, 2025.

    MRK Earnings Call

    The latest MRK earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, MRK beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $18.09B, up 4.7% from $17.28B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.49$2.12$1.80 - $2.26+17.45%Beat-3.5%181 up, 7 downOct 29, 2026$18.09B
    Jun 30, 2026-$0.13-$0.26-$0.40 - -$0.03+50.00%Beat-106.1%180 up, 0 downAug 4, 2026$16.61B
    Mar 31, 2026-$1.28-$1.47-$1.81 - -$0.83+12.93%Beat-157.7%206 up, 7 downApr 30, 2026$16.29B
    Dec 31, 2025$2.04$2.01$1.97 - $2.11+1.49%Beat+18.6%171 up, 8 downFeb 3, 2026$16.40B
    Sep 30, 2025$2.58$2.35$2.29 - $2.47+9.79%Beat+64.3%183 up, 5 downOct 30, 2025$17.28B
    Jun 30, 2025$2.13$2.03$1.88 - $2.17+4.93%Beat-6.6%174 up, 8 downJul 29, 2025$15.81B
    Mar 31, 2025$2.22$2.14$2.08 - $2.25+3.74%Beat+7.2%165 up, 3 downApr 24, 2025$15.53B
    Dec 31, 2024$1.72$1.67$1.59 - $1.85+2.99%Beat+5633.3%151 up, 9 downFeb 4, 2025$15.62B
    Sep 30, 2024$1.57$1.57$1.33 - $1.850.00%In line-26.3%150 up, 2 downOct 31, 2024$16.66B
    Jun 30, 2024$2.28$2.14$2.03 - $2.24+6.54%BeatN/A166 up, 0 downJul 30, 2024$16.11B
    Mar 31, 2024$2.07$1.92$1.76 - $2.12+7.81%Beat+47.9%173 up, 4 downApr 25, 2024$15.78B
    Dec 31, 2023$0.03-$0.11-$0.17 - -$0.02+127.27%Beat-98.1%183 up, 3 downFeb 1, 2024$14.63B
    Sep 30, 2023$2.13$1.95$1.69 - $1.96+9.23%Beat+15.1%176 up, 1 downOct 26, 2023$15.96B
    Jun 30, 2023-$2.06-$2.18-$2.32 - -$1.99+5.50%Beat-210.2%180 up, 9 downAug 1, 2023$15.04B
    Mar 31, 2023$1.40$1.34$1.20 - $1.46+4.48%Beat-34.6%197 up, 2 downApr 27, 2023$14.49B
    Dec 31, 2022$1.62$1.54$1.48 - $1.74+5.19%Beat-10.0%197 up, 0 downFeb 2, 2023$13.83B
    Sep 30, 2022$1.85$1.71$1.55 - $1.86+8.19%Beat+5.7%174 up, 3 downOct 27, 2022$14.96B
    Jun 30, 2022$1.87$1.71$1.57 - $1.80+9.36%Beat+42.7%166 up, 2 downJul 28, 2022$14.59B
    Mar 31, 2022$2.14$1.83$1.55 - $2.09+16.94%Beat+52.9%166 up, 2 downApr 28, 2022$15.90B
    Dec 31, 2021$1.80$1.52$1.22 - $1.66+18.42%Beat+36.4%173 up, 1 downFeb 3, 2022$13.52B
    Sep 30, 2021$1.75$1.55$1.36 - $1.67+12.90%Beat+0.6%12N/AOct 28, 2021$13.15B
    Jun 30, 2021$1.31$1.35$1.18 - $1.41-2.96%Miss-4.4%12N/AJul 29, 2021$11.40B
    Mar 31, 2021$1.40$1.61$1.55 - $1.75-13.04%Miss-6.7%15N/AApr 29, 2021$10.63B
    Dec 31, 2020$1.32$1.39$1.29 - $1.49-5.04%Miss+13.8%16N/AFeb 4, 2021$9.18B
    Sep 30, 2020$1.74$1.43$1.19 - $1.55+21.68%Beat+15.2%14N/AOct 27, 2020$10.93B
    Jun 30, 2020$1.37$1.09$0.70 - $1.24+25.69%Beat+5.4%13N/AJul 31, 2020$9.35B
    Mar 31, 2020$1.50$1.34$1.16 - $1.44+11.94%Beat+23.0%14N/AApr 28, 2020$12.06B
    Dec 31, 2019$1.16$1.15$1.10 - $1.19+0.87%Beat+11.5%14N/AFeb 5, 2020$4.15B
    Sep 30, 2019$1.51$1.24$1.17 - $1.28+21.77%Beat+26.9%13N/AOct 29, 2019$12.40B
    Jun 30, 2019$1.30$1.16$1.09 - $1.20+12.07%Beat+22.6%12N/AJul 30, 2019$11.76B
    Mar 31, 2019$1.22$1.05$1.01 - $1.10+16.19%Beat+16.2%12N/AApr 30, 2019$10.82B
    Dec 31, 2018$1.04$1.03$1.00 - $1.08+0.97%Beat+6.1%11N/AFeb 1, 2019$11.00B
    Sep 30, 2018$1.19$1.14$1.10 - $1.19+4.39%Beat+7.2%12N/AOct 25, 2018$10.79B
    Jun 30, 2018$1.06$1.03$1.00 - $1.05+2.91%Beat+5.0%13N/AJul 27, 2018$10.46B
    Mar 31, 2018$1.05$1.00$0.95 - $1.10+5.00%Beat+19.3%16N/AMay 1, 2018$10.04B
    Dec 31, 2017$0.98$0.94$0.90 - $0.96+4.26%Beat+10.1%17N/AFeb 2, 2018$10.43B
    Sep 30, 2017$1.11$1.03$0.99 - $1.08+7.77%Beat+3.7%16N/AOct 27, 2017$10.32B
    Jun 30, 2017$1.01$0.87$0.85 - $0.90+16.09%Beat+8.6%16N/AJul 28, 2017$9.93B
    Mar 31, 2017$0.88$0.83N/A+6.02%Beat-1.1%N/AN/AMay 2, 2017$9.43B
    Dec 31, 2016$0.89$0.89N/A0.00%In line-4.3%N/AN/AFeb 2, 2017$10.12B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $8.97, up 17.4% from the year before. It was $3.78 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$8.97+17.4%
    Dec 31, 2024$7.64+409.3%
    Dec 31, 2023$1.50-79.9%
    Dec 31, 2022$7.48+19.5%
    Dec 31, 2021$6.26+5.6%
    Dec 31, 2020$5.93+14.3%
    Dec 31, 2019$5.19+19.6%
    Dec 31, 2018$4.34+9.0%
    Dec 31, 2017$3.98+5.3%
    Dec 31, 2016$3.78N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,48318
    2026Q2Jun 30, 20266,33817
    2026Q1Mar 31, 20267,03917
    2025Q4Dec 31, 20258,53816
    2025Q3Sep 30, 20257,64617
    2025Q2Jun 30, 20259,34919
    2025Q1Mar 31, 20258,79216
    2024Q4Dec 31, 20248,97618

    2026Q3 Earnings Call

    Opening remarks

    Peter Dannenbaum Senior Vice President of Investor Relations Thank you, Julie, and good morning, everyone. Welcome to the third-quarter 2026 conference call for Merck & Co., Inc., Rahway, New Jersey, USA. Speaking on today's call will be Robert Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Y. Li, President of Merck Research Labs. Before we get started, I would like to point out that we have items in our GAAP results, such as acquisition-related charges, restructuring costs, and certain other items, that we have excluded from our non-GAAP results. There is a reconciliation in our press release. I will also remind you that some of the statements that we make may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 2000. Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A in the 10-Ks, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck & Co., Inc., Rahway, New Jersey, USA, undertakes no obligation to publicly update any forward-looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks, and our SEC filings, are all posted to the Investor Relations section of our company's website. With that, I would like to turn the call over to Robert.

    Robert Davis Chairman and Chief Executive Officer Thank you, Peter. Good morning, and thank you for joining today's call. 2026 continues to be a year of substantial progress for our company. We are executing well on all fronts, demonstrated particularly by the many new product launches now successfully underway and the important clinical milestones we are achieving that are further derisking the substantial long-term opportunity of our late-phase pipeline. This momentum extends across multiple therapeutic areas and modalities, and there is much more to come, with numerous significant readouts still to occur over the coming years. I am very pleased with how the disciplined execution of our strategy over the past several years is increasingly translating into meaningful clinical, regulatory, and commercial results. The breadth of these achievements strengthens my confidence in the future of our company and our ability to deliver long-term value for patients and shareholders. Turning to our third-quarter results, we delivered solid performance with revenue of $18.1 billion, reflecting increased contributions from new products, as well as strength in oncology and animal health.

    Frequently Asked Questions About MRK

    When is Merck & Company's next earnings date?

    Merck & Company's next earnings report is expected for Feb 2, 2027.

    Did MRK beat earnings estimates last quarter?

    Yes. Merck & Company reported EPS of $2.49 for the quarter ended Sep 30, 2026, above the $2.12 estimate, a 17.45% surprise.

    What EPS do analysts expect from MRK next quarter?

    The consensus EPS estimate for Merck & Company for the quarter ending Dec 31, 2026 is $1.76 from 19 analysts, with estimates from $1.67 to $2.01.

    How often does MRK beat earnings estimates?

    Merck & Company beat the EPS estimate in each of the last 8 quarters, with an average surprise of +12.91%.